AU Patent

AU2022379998A1 — Methods for administration of drug to the retina

Assigned to Georgia Tech Research Corp · Expires 2024-05-09 · 2y expired

What this patent protects

Methods are provided for administering a therapeutic agent to an eye of a patient, wherein the method includes (i) inserting a microneedle into the eye of the patient, wherein the microneedle extends through the sclera and choroid layers, but not into the vitreous, and without a …

USPTO Abstract

Methods are provided for administering a therapeutic agent to an eye of a patient, wherein the method includes (i) inserting a microneedle into the eye of the patient, wherein the microneedle extends through the sclera and choroid layers, but not into the vitreous, and without a vitrectomy or a retinotomy; and (ii) injecting a fluid comprising a therapeutic agent through a lumen of the microneedle and into a subretinal space of the eye, wherein the microneedle has (i) a beveled tip with a bevel angle from 40º to 70º and (ii) an outer diameter that is less than 150 µm.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022379998A1
Jurisdiction
AU
Classification
Expires
2024-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Georgia Tech Research Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.